CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2025 (the “Grant Date”) that were approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired...
NEW YORK , Sept. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) breached their fiduciary duties to shareholders.
Just because a stock has been battered doesn't make it an automatic buy. That's only the case if it can bounce back, and in some cases, there are few good reasons to believe it can.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne and five to siblings of individuals living with Duchenne. Now in ...
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pic...
NEW YORK--(BUSINESS WIRE)---- $SRPT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruq...
LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws. Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm befor...
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"), of the important August 25, 2025 lead plaintiff deadline. So What: If you purchased Sarepta Therapeutics securities during the Class Peri...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.